Methylenedioxymethamphetamine (MDMA)

MDMA (Ecstasy) and Harm Reduction

(MDMA (Ecstasy) and Harm Reduction) "In the context of new synthetic drugs there are some well-established approaches to reduce harm such as handing out condoms for free or giving out drinking water to reduce or stabilise body temperature and to avoid heatstroke. In addition, there are possible harms in the party scene that can be countered by pill-testing projects only. All pill-testing projects inform consumers about very dangerous and unexpected pills on site, through magazines and posters or through the Internet."

MDMA Therapy Benefits

(MDMA Therapy Benefits) "It is notable that no subjects reported any harm from study participation and all of them reported some degree of benefit. Consistent with the investigators‘ clinical observations in the original study, the responses we obtained on the questionnaire indicated that participants often experienced benefits beyond decreased PTSD symptoms.

MDMA Therapy and Substance Abuse

(MDMA Therapy and Substance Abuse) "The data we obtained about illicit drug use from the LTFU [Long Term Follow Up] Questionnaire supports the hypothesis that MDMA can be administered in a clinical setting with minimal risk that the subjects will subsequently seek out and self-administer 'street ecstasy,' or become dependent on the drug.

Global Amphetamine-Type Stimulant Use, 2011

(Global Amphetamine-Type Stimulant Use, 2011) "Use of ATS, excluding 'ecstasy', remains widespread globally, and appears to be increasing. Although prevalence estimates are not available from Asia and Africa, experts from these regions continue to report a perceived increase in the use of ATS. While the use of ATS was already a problem in East and South-East Asia, there are reports of increasing diversion of precursor chemicals, as well as increased seizures and manufacture of methamphetamine, combined with an increase in its use.

Neurocognitive Effects from Long-Term MDMA Use

(Neurocognitive Effects from Long-Term MDMA Use) "Using this rigorous approach, we found few consistent differences between ecstasy users and non-users on wide-ranging measures of verbal and visuospatial memory, verbal fluency, attention, processing speed, manipulative dexterity and executive cortical functions. Ecstasy users exhibited lower vocabulary scores than non-users, but this finding probably indicates differences in pre-morbid ability rather than neurotoxicity of ecstasy, as vocabulary is generally preserved even after neurological insults [26,45,46].

MDMA (Ecstasy or Molly), Sociability and Empathy

(MDMA (Ecstasy or Molly), Sociability and Empathy) "We found that MDMA (1.5 mg/kg only) altered a behavioral indicator of social cognition. Specifically, it robustly reduced recognition of fearful faces, without changing recognition of other emotions from facial or vocal cues. Although previous studies have confirmed that the drug induces subjective feelings related to sociability and empathy, this is the first published demonstration of an overt behavioral effect of MDMA in humans."

Effectiveness of MDMA (Ecstasy or Molly) in Psychotherapy

(Effectiveness of MDMA (Ecstasy or Molly) in Psychotherapy) "This pilot study demonstrates that MDMA-assisted psychotherapy with close follow-up monitoring and support can be used with acceptable and short-lived side effects in a carefully screened group of subjects with chronic, treatment-resistant PTSD. In this group, MDMA-assisted psychotherapy compared with the same psychotherapy with inactive placebo produced clinically and statistically significant improvements in PTSD symptoms as measured by standard symptom scales.

Ecstasy Production in Canada, 2009

(Ecstasy Production in Canada, 2009) "In 2009, an abundant supply of Canadian-produced MDMA continued to meet domestic consumption requirements, as well as provide significant quantities for international markets.40 Domestic prices for MDMA remained at the record low levels from 2008, while purity levels of the drug remained high, or even may have increased. The nature or extent of MDMA production in Canada appeared to be unaffected by the significant shortage in the supply of MDP2P, that reportedly impacted European markets.